CeMines to Present at Medtech Insight's ``Investment In Innovation'' Conference.

IRVINE, Calif. -- CeMines(TM) announced that it will present at Medtech Insight's Prestigious "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" Conference, taking place February 10-11, 2005, at the Hyatt Regency Irvine in Irvine, California.

CeMines is focused on the development and commercialization of clinical diagnostic tests and targeted therapeutics for cancer. "Central to our scientific discipline is a long-term clinical strategy based on our underlying belief that cost-effective patient care and healthcare reform initiatives must eliminate unnecessary cost elements and duplicative legacy procedures," said Roger Attick, president and chief executive officer.

CeMines is preparing to commercialize a family of cancer diagnostic products under the brand: CellCorrect(TM). The Company is targeting lung, breast, GI and prostate cancers. CeMines is also undertaking preliminary research into unique therapeutic drugs against cancer, capable of controlling cell regulatory mechanisms.

The Company's discoveries are founded on an emerging field of science known as "gene regulation" -- the ability to monitor, target and control the body's cellular regulatory mechanisms. The Company's early research, dating back to 2000, identified unique biomarkers and analysis techniques to interpret the information they contain. Biomarkers establish the profile (or molecular fingerprint) of a specific disease. Further, CeMines is also developing bioinformatics applications.

The Company's bioinformatics platform is called CeMines Molecular FingerPrinting(TM). It allows the identification of unique pathways (or Fingerprints) of gene and protein expression, in both malignant and non-malignant cells. "CeMines Molecular FingerPrinting will detect and identify cancer and pre-cancerous cells earlier, and with greater accuracy," said Attick. "We are convinced this is a much more desirable approach than is available through more invasive legacy techniques such as biopsy, CT and PET scans or endoscopies. Further, we believe the future of targeted therapeutics (i.e., personalized medicine) will be based on CeMines Molecular FingerPrint profiles."

CeMines Point of Care(TM) and CeMines Molecular FingerPrinting are the two primary components of a comprehensive, bioinformatics-based clinical care model. CeMines' strategic direction is to empower physicians and healthcare specialists to provide superior care for patients with complex diseases, such as cancer, at a much lower cost. "It is our objective to offer healthcare providers a choice to reduce or eliminate unnecessary and costly third-party procedures," Attick said. "More important to CeMines is knowing that physicians and patients are made aware of the patient's condition sooner, thereby establishing a less reactive approach to treatment."

Now a division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. To register for In3 Irvine or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.